Société Industrielle Limousine d'Application Biologique
SILAB Group is a French group and world leader in the field of natural active ingredients which now aims to expand its activities in the field of regenerative medicine. SILAB is an innovation driven French company, which creates, manufactures and sells efficiency-proven active ingredients to the cosmetic industry. It has been set up in 1984 by Jean Paufique, biologist and brilliant entrepreneur, who is President and General Manager of the SILAB group companies.
SILTISS, created in 2016, is a subsidiary of the SILAB group. SILTISS is dedicated to the development, production and marketing of biomaterials of natural origin that promote tissue regeneration processes. The first applications concern class III medical devices, as bone substitutes for the orthopaedic, dental and maxillofacial surgery. Other applications in the field of wound healing and regeneration are already in the development phase. SILTISS considers the introduction of an alternative to bone substitutes of animal origin as a real breakthrough and has developed a bone substitute from biopolymers: GlycoBone®. SILAB and SILTISS are linked as SILAB provides financial and Human Resources support as well as expertise in Quality Management, and other key resources to SILTISS.
INSERM’s Laboratory for Vascular Translational Science has developed a strong partnership with the SILAB group to produce the 3D scaffolds. Glycobone® is an osteoinductive and injectable ready-to-use polysaccharide-based scaffold combined with hydroxyapatite tailored for oral bone defect reconstruction. This class III medical device is under industrial co-development by INSERM/SILAB group and is expected to be introduced in clinical practice in the course of TBMED.
In addition to the use of GlycoBone® as a case study in TBMED, which includes the production of the medical device, the scaling-up and packaging and preparing the regulatory toxicology dossier, SILAB group will be involved as the sponsor of two clinical trials.